Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 58, Issue -, Pages 111-113Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2020.09.001
Keywords
antagomiRs; ARDS; Coronavirus; COVID-19; Cytokine storm; microRNAs
Categories
Ask authors/readers for more resources
In the face of cytokine storm in COVID-19, current experimental therapies, while somewhat relieving, are unable to completely prevent the storm. AntagomiRs may serve as an effective and safe alternative treatment customizable to the disease specificity and applicable to other coronaviruses.
Is it possible to develop a reliable, safe treatment for the widespread COVID-19 pandemic shortly? COVID-19 is characterized by a disruptive cytokine storm, quickly and often irreversibly damaging the patient?s lungs, as its main target organ, leading to lung failure and death. Actual experimental therapies are trying to reduce the activation of some specific cytokines, such as IL-6, somewhat reducing the burden for the patient. However, they are often unable to block the whole storm occurring at the cytokine level. In presence of the cytokine storm, especially in severe patients, antagomiRs, already demonstrated to be efficient and secure in cardiovascular disease, could represent a useful alternative to such treatment, customizable upon the disease specificities and applicable to other coronaviruses possibly associated with such clinical manifestations, while a reliable, efficient vaccine is being distributed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available